All studies
Phase not statedRecruitingObservationalNCT06924021

Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)

  • Age-Related Macular Degeneration
I want to take partRefer a patient2 sites in India · 15 worldwide

At a glance

Phase
Phase not stated
Study type
Observational
Sponsor
University of Wisconsin, Madison
Enrolment target
1,000
Started
12 May 2025
Main results due (estimated)
June 2027
Study ends (estimated)
June 2027
Observational model
Cohort
Time perspective
Prospective
Sites
15 · 2 in India
First posted
11 April 2025
Registry updated
30 October 2026

Can you take part?

  • Aged 50 years and over.
  • Open to any sex.
  • Healthy volunteers can take part.
  • Who they are looking for: Approximately 1000 participants from up to 25 sites in the United States, Europe, Asia, South America, Africa, and Australia will be enrolled and balanced by age, sex, and AMD level (worse eye selected as study eye). Every region listed above may not be represented and additional regions/countries not listed above may be included.

Age groups: adult, older adult. Sampling: non probability sample.

These are the headline rules. Every study has a longer list, and whether you are eligible is decided by the research team at the site, never by this page.

Read the full eligibility criteria
Inclusion Criteria:

* Participants greater than or equal to 50 years of age at time of signing Informed Consent Form
* Willing to comply with all study procedures and sign the Informed Consent Form (ICF)
* Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center.

Exclusion Criteria:

* Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed.
* Unable to acquire adequate quality images, as evaluated by the Central Reading Center
* Severe vision loss requiring urgent surgery
* Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light
* A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study
* Unwilling to sign informed consent form
* Currently or previously enrolled in an interventional AMD clinical trial

What this study is about

In the sponsor’s own words, from the registry.

1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.

Read the detailed description

Age-related macular degeneration (AMD) is a leading cause of blindness in the world. The early and intermediate stages of AMD progress to late stage resulting in vision loss due to either geographic atrophy or neovascular AMD. Preventive measures to reduce treatment burden and prevent blindness are important. While there are no approved therapies for early disease, active research is underway. However, advancing therapeutic trials for AMD prevention remains challenging due to the lack of primary care involvement in early-stage AMD diagnosis.

A clear need exists for a reliable screening tool, deployable in optometry or primary care facilities to identify those with an early stage of disease. While an Artificial Intelligence (AI) based screening tool would be an ideal solution, there are obstacles to its prospective validation due to difficulty in enrolling sufficient cases in a screening environment. A key step towards promoting this field lies in collecting a diverse dataset of multimodal imaging and providing a reference standard level 1 classification from a wide array of patients with AMD. Having such a benchmark dataset available for research purposes will empower the development and validation of AI models for AMD. This data can serve as the much-sought pathway to the rapid development of screening models, facilitating the referral of patients with the appropriate disease spectrum, and ultimately leading to the prevention of late AMD.

This is a prospective, cross-sectional, multi-center, observational study to collect and develop a meticulously curated and diverse AMD benchmark dataset, featuring reference standard level 1 classification and comprehensive annotation of images.

Study procedures include:

* Patient history: demographics (age, sex, ethnicity, race), smoking history, family history of AMD * Physical exam: height and weight * Snellen best-corrected visual acuity (BCVA) * AMD classification (Beckman scale)

Eligible participants will undergo one retinal imaging session of both eyes for the following:

* Single field stereo color fundus photography (cFP) - pre and post dilation * Macular spectral domain-optical coherence tomography (SD-OCT)

Due to the need for diversity in the dataset, sites need to represent a wide array of geographical locations. In addition, balancing will be done on enrolled participants with or without AMD including age, sex, and AMD level (worse eye selected as study eye).

Keywords: screening · artificial intelligence · AI

What participants receive

  • AMD Benchmark Imaging Dataset Cohort

    Study Procedures Include: * Patient history: demographics (age, sex, ethnicity, race), smoking history, family history of AMD * Physical exam: height and weight * Snellen best-corrected visual acuity (BCVA) * AMD classification (Beckman scale)

    Other: Retinal Imaging

Interventions

  • Retinal ImagingOther

    Also known as Single field stereo color fundus photography, Macular spectral domain-optical coherence tomography

    Eligible participants will undergo one retinal imaging session of both eyes for the following: * Single field stereo color fundus photography (cFP) - pre and post dilation * Macular spectral domain-optical coherence tomography (SD-OCT)

What the study measures

Primary outcomes

  1. AMD Classification by Participant Count

    A meticulously curated and diverse Benchmark dataset, featuring reference standard level 1 classification and annotated images for a wide range of AMD phenotypes is the primary outcome. Diversity of the dataset will in part be measured by classifying AMD status. The goal is to have: * 20% participants with no AMD * 30% participants with Early AMD * 30% participants with Intermediate AMD * 10% participants with Geographic Atrophy (GA) * 10% participants with Neovascular age-related macular degeneration (nAMD)

    Time frame: up to 18 months

  2. Geographic Location by Participant Count

    A meticulously curated and diverse Benchmark dataset, featuring reference standard level 1 classification and annotated images for a wide range of AMD phenotypes is the primary outcome. Diversity of the dataset will in part be measured by geographic location. 1000 participants from up to 25 global sites will be included.

    Time frame: up to 18 months

Who is running it

Lead sponsor
University of Wisconsin, Madison
Sponsor type
Other
Responsible party
The sponsor
Organisation
University of Wisconsin, Madison
Data monitoring committee
No
US FDA-regulated drug
No
US FDA-regulated device
No
Sponsor's study ID
2025-0059
Other IDs
Protocol Version 3/14/2025, A536070
  • Amitha Domalpally, MD, PhD

    Principal investigator

    UW School of Medicine and Public Health

Study sites(15)

  • Sankara Nethralaya, Medical Research Foundation

    Chennai, Tamil Nadu, India

    Recruiting

  • Aravind Eye Hospital

    Chennai, Tamil Nadu, India

    Recruiting

  • Emory University

    Atlanta, Georgia, United States

    Recruiting

  • Bergstrom Eye Research LLC

    Fargo, North Dakota, United States

    Recruiting

  • Erie Retina Research

    Erie, Pennsylvania, United States

    Recruiting

  • Retina Foundation of the Southwest

    Dallas, Texas, United States

    Recruiting

  • Valley Retina Institute

    McAllen, Texas, United States

    Recruiting

  • Retina Consultants of Texas (Houston)

    The Woodlands, Texas, United States

    Recruiting

  • University of Utah - John A. Moran Eye Center

    Salt Lake City, Utah, United States

    Recruiting

  • University Station Eye Care Clinic

    Madison, Wisconsin, United States

    Recruiting

  • Adelaide Eye and Retina Centre

    Adelaide, Australia

    Recruiting

  • Aga Khan University

    Karachi, Pakistan

    Recruiting

  • Kim Eye Hospital

    Seoul, South Korea

    Recruiting

  • Charles Research Center

    Buenos Aires, Argentina

    Not yet recruiting

  • University of Bonn - Department of Ophthalmology

    Bonn, Germany

    Not yet recruiting

Showing 15 of 15 sites. 13 recruiting, 2 not recruiting and 0 cancelled; 2 in India. Not recruiting covers sites not yet open, finished enrolling, completed or paused; cancelled covers sites withdrawn before opening or stopped for good.

References and data sharing

Participant data shared
No

Source: ClinicalTrials.gov record NCT06924021, status verified March 2026. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.

Take part

Interested in this study?

Tell us how to reach you and we will connect you with the study team. Or refer someone you care for, with their permission.

A person reads this, not a bot. We are not doctors, this is not medical advice, and it is not for emergencies.

Not the right study?

Every study recruiting in India, one search away.